Coronavirus Notebook: EMA Expects First Vaccine Efficacy Data Soon, ACT-Accelerator Needs Urgent Funding
Talks are continuing on COVID-19 vaccine supply in the EU, with Pfizer/BioNTech’s BNT-162 the latest in the frame for the delivery of 200 million doses. The European Commission has also said that if the vaccines fail to perform, any money paid in advance purchase deals should go towards further research.
You may also be interested in...
Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.
InflaRx and Relief Therapeutics/NeuroRx are investigating potential new treatments for COVID-19-induced pneumonia and for coronavirus-related ARDS.
While AZ awaits an independent review, its CEO maintains the vaccine could soon be back on track for a late 2020/early 2021 approval.